Latest news with #NewChemicalEntity
Time of India
08-07-2025
- Business
- Time of India
Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
The initial public offering (IPO) of Anthem Biosciences will open for subscription on Monday, July 14. The Bengaluru-based CRDMO player is planning to raise Rs 3,395 crore through the issue. The issue will conclude on Wednesday, July 16. About Anthem Biosciences IPO The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan. About Anthem Biosciences Anthem's business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Live Events Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company. The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025. According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026. Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report. Anthem Biosciences financials Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24. Sai Life Sciences Limited, Syngene International Limited , Cohance Lifesciences Limited , (Formerly Suven Pharmaceuticals) and Divi's Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP. Anthem Biosciences lead managers The Book Running Lead Managers to the offer are JM Financial Limited , Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The equity shares are proposed to be listed on BSE and NSE.
Associated Press
28-02-2025
- Business
- Associated Press
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan planned for 2025, and launch, if approved, is expected during 2026 Daridorexant is launched in Japan as QUVIVIQ™ and is in Phase 3 trials in South Korea Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) announces that it has entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. ('Holling') for daridorexant in Taiwan. Daridorexant is an oral dual orexin receptor antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep. According to Taiwan's National Health Research Institutes, sleep disorders such as insomnia affected 12-20% of the adult population in 2021, approximately 4-5 million people. Under the terms of the agreement, Nxera will be responsible for the supply of drug product and Holling will be responsible for regulatory, commercial and distribution activities and will hold all regulatory approvals. Holling expects to file a New Chemical Entity (NCE) to the Taiwan Food and Drug Administration (FDA) in mid-2025, which if approved would lead to an expected launch in mid-2026. Nxera will receive an upfront payment on signing and is eligible for near-term regulatory and sales milestones plus royalties on net sales from Holling, as well as revenue on the supply of drug product to Holling. Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: 'This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the growing population of patients suffering with insomnia in Taiwan. Holling's wealth of experience as a leading commercial distributor in Taiwan makes it the ideal partner and we look forward to working together to prepare daridorexant for filing and launch, if approved, in 2026. This latest agreement is part of our strategy to expand access to innovative medicines in Japan and throughout the APAC region, working with leading regional commercialization partners for products targeting larger patient populations while leveraging our internal capabilities in specialty medicine and rare diseases.' –END– About Daridorexant Daridorexant is a dual orexin receptor antagonist that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. Daridorexant 25mg and 50mg was approved in Japan in September 2024 and launched under the brand name of QUVIVIQ™ by Nxera Pharma Japan ('NPJ') and Shionogi in December 2024. Nxera is also conducting a Phase 3 trial with daridorexant in adults with insomnia in South Korea. QUVIVIQ™ is approved in the US, Europe and certain other countries and marketed in these territories by Idorsia Pharmaceuticals Ltd. * QUVIVIQ™ is a trademark of Idorsia Ltd. About Insomnia Disorder Insomnia disorder is defined as difficulty initiating or maintaining sleep, causing clinically significant distress or impairment in important areas of daytime functioning. As defined this impact on sleep quantity or quality should be present for at least three nights per week, lasts for at least three months, and occurs despite an adequate opportunity to sleep. Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. According to Taiwan's National Health Research Institutes, sleep disorders such as insomnia affected 12-20% of the adult population in 2021, approximately 4-5 million people. Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Research has shown that poor quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels. The goal of treatments for insomnia is to improve sleep quality and quantity, as well as daytime functioning, while avoiding adverse events and next-morning residual effects. Current recommended treatment of insomnia includes sleep hygiene therapy, cognitive behavioral therapy, and pharmacotherapy. About Holling Bio-Pharma Corp. Headquartered in Taipei, Taiwan, Holling Bio-Pharma has been established for nearly five decades and is now the largest pharmaceutical distributor in Taiwan. Over the years, Holling Bio-Pharma primarily work with companies with innovate products and has continuously introduced the latest therapeutic drugs ranging from small molecule drugs and biologics to vaccines to help patients in Taiwan combat various diseases. With a fully equipped and professional team, Holling Bio-Pharma offers comprehensive services including drug registration, market access, product promotion, warehousing, and logistics. Holling Bio-Pharma also has extensive experience and expertise in the CNS field, with successful launch of innovative CNS products from both EU and US. The company is committed to delivering high-quality services that meet international standards, ensuring the latest medical innovations reach patients efficiently and effectively. About Nxera Pharma Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). Enquiries: Nxera – Media and Investor Relations Kentaro Tahara, VP Investor Relations and Corporate Strategy Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |[email protected] MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
